ORIGINAL RESEARCH article
Front. Neurol.
Sec. Epilepsy
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1564735
Long-term outcome of vagus nerve stimulation therapy in drug-resistant epilepsy: a retrospective single-center study
Provisionally accepted
- Qilu Hospital, Shandong University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Vagus nerve stimulation (VNS) has garnered widespread application in patients with drug-resistant epilepsy (DRE), while the efficacy and prognostic factors of VNS in DRE remain elusive. Moreover, clinical determinants associated with rapid response to VNS have never been uncovered. This study aimed to elucidate factors influencing efficacy and rapid response to VNS. Methods: A consecutive series of patients with DRE undergoing VNS surgery from January 2014 to December 2023 was collected to describe VNS efficacy. Both univariate and multivariate analyses were performed to identify statistically significant prognostic factors, and a predictive model was developed. Furthermore, we examined clinical determinants of rapid/slow response to VNS and VNS current changes. Results: A total of 65 patients underwent VNS implantation. Seizure frequency significantly decreased post-VNS, with mean seizure reduction rates of 35.7%, 49.0%, 48.5%, 52.8%, 63.2%, and 66.8% at 6 (n=65), 12(n=65), 24(n=50), 36(n=40), 60(n=31), and 84(n=19) months, respectively. At final follow-up, 61.5% (40/65) were responders (50–100% seizure reduction), and 10.8% (7/65) achieved seizure freedom for ≥ 1 year. Univariate analysis identified age at seizure onset ≥ 6 years (p = 0.003), baseline seizure frequency ≤ 30/month (p = 0.001), focal seizures (p = 0.002), developmental and epileptic encephalopathies (p = 0.037), and surgical history (p < 0.001) as significant prognostic factors. Multivariate analysis confirmed age at seizure onset ≥ 6 years (OR: 5.726, p = 0.039), baseline seizure frequency ≤ 30/month (OR: 4.697, p = 0.048), and focal seizures (OR: 4.791, p = 0.025) as independent predictors, enabling the development of a predictive model for VNS efficacy. Additionally, among responders, the median response duration was 6 months (range: 1–60 months), with baseline seizure frequency ≤ 30/month significantly associated with rapid response of VNS in DRE (< 6 months, p = 0.033). Conclusions: VNS is effective for treating DRE, with efficacy increasing with follow-up duration. Age at seizure onset ≥ 6 years, baseline seizure frequency ≤ 30/month, and focal seizure were predictive of VNS success, underscoring the need for careful preoperative assessment of patients with DRE before VNS surgery.
Keywords: Epilepsy, Vagus Nerve Stimulation, Drug-resistant epilepsy, prognostic factors, Rapid response
Received: 22 Jan 2025; Accepted: 25 Apr 2025.
Copyright: © 2025 Chen, Yang, Xu, Li, Li, Yang, Yang, Wang, Xu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shuo Xu, Qilu Hospital, Shandong University, Jinan, China
Xiuhe Zhao, Qilu Hospital, Shandong University, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.